Table 3.
The levels of IL‐17, IL‐6, IL‐23, IL‐10, and TGF‐β1
| Conventional group (n = 32) | Intensive group (n = 34) | |
|---|---|---|
| IL‐17 (pg/mL) | ||
| Pretherapy | 70.19 ± 28.13 | 71.50 ± 31.55 |
| Post‐therapy | 41.54 ± 17.43* | 32.20 ± 12.90*▲ |
| ΔIL‐17 | 28.64 ± 14.21 | 39.29 ± 19.95▲ |
| IL‐6 (pg/mL) | ||
| Pretherapy | 49.19 ± 22.08 | 48.28 ± 20.80 |
| Post‐therapy | 32.98 ± 15.99* | 16.45 ± 8.16*▲ |
| △IL‐6 | 16.20 ± 8.87 | 31.82 ± 13.67▲ |
| IL‐23 (pg/mL) | ||
| Pretherapy | 669.25 ± 311.01 | 31.82 ± 13.67▲ |
| Post‐therapy | 296.78 ± 175.08* | 684.27 ± 355.42 |
| △IL‐23 | 372.47 ± 171.80 | 202.68 ± 107.94*▲ |
| IL‐10 (pg/mL) | ||
| Pretherapy | 6.06 ± 2.71 | 6.20 ± 3.18 |
| Post‐therapy | 9.95 ± 4.55* | 12.28 ± 3.94*▲ |
| △IL‐10 | 3.89 ± 2.46 | 6.08 ± 1.86▲ |
| TGF‐β1 (pg/mL) | ||
| Pretherapy | 391.90 ± 192.67 | 398.81 ± 189.42 |
| Post‐therapy | 650.14 ± 327.70* | 834.31 ± 370.05*▲ |
| △TGF‐β1 | 258.24 ± 173.69 | 435.50 ± 214.92▲ |
Note: Compared with pretherapy *P<.05; Compared with conventional group ▲ P<.05.